Celularity Inc

GX Acquisition Corp. II (Nasdaq: GXGX), sponsored by GX Sponsor II LLC, was a blank-check company that completed its initial public offering in 2020 with a focus on the healthcare and biotechnology sector. In May 2021, the SPAC filed an 8-K with the SEC in connection with its announced business combination with Celularity Inc., a clinical-stage biotechnology company specializing in cell-based therapeutics derived from the human placenta. The transaction ultimately brought Celularity to the public markets, where it traded under the ticker CELU following deal close. The filing marked a significant milestone in the SPAC's path from IPO through its de-SPAC transition. Sign up for full data, filings, and analytics on SpacDesk at spacdesk.com.